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Previewsrecombinant GM-CSF has been trialed as
a treatment for IBD, with a high incidence
of adverse effects offsetting the reduction
of disease activity. Auto-antibodies to
GM-CSF have been detected in patients
with ileal CD and bc receptor expres-
sion on granulocytes and monocytes is
repressed in patients with IBD, particu-
larly UC patients, collectively suggesting
that GM-CSF-bc signaling is suboptimal
in IBD (Goldstein et al., 2011). How these
past findings play into the role of the IL-
23-GM-CSF-eosinophil axis in IBD, is
unclear. Disease heterogeneity and the
different roles for IL-23 that are observed
in IBD subtypes are likely to be important
in this respect (Kobayashi et al., 2008).
However, once validated in specific sub-
groups (endotypes) of patients, these
findings are likely to offer significant ad-
vances in IBD therapies. Anti-IL-5 thera-
pies are already in advanced stages of
clinical trials for eosinophilic disease and
allergy and are readily transferrable to
IBD management. Similarly, anti-IL-23
monoclonal therapies are in clinical trials
for IBD and eliminating the Th17 cell-
eosinophil axis may prove more effective
than anti-TNF-a therapies. A more simple
therapeutic approach might be inhibitingeosinophil peroxidase (EPO) with antioxi-
dants and thus limiting the major factor
inducing the lesions observed in these
studies. Of note, rectal administration
of vitamin E, a potent anti-oxidant, has
shown some efficacy in mild-moderate
ulcerative colitis (Mirbagheri et al., 2008)
and ironically, inhibition of peroxidase ac-
tivity by the free-radical scavenging prop-
erties of cigarette smoke might explain
the reported beneficial effects of smoking
in UC patients because cigarette smoke
can directly inhibit EPO activity. However,
human IBD is complex and there is likely
to be redundancy across multiple effector
pathways that operate in parallel. The
findings of Griseri et al. might nonetheless
lead to significant advances in our under-
standing of immunopathology, chronicity,
and distinction of phenotypic differences
in IBD subtypes. Whether these findings
also extend to Th17-mediated diseases
in other organs will be of considerable
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Passenger mutations specific to particular mouse strains can distort experimental outcomes. In this issue of
Immunity, VandenBerghe et al. (2015) demonstrate that passengermutations are frequent inmost genetically
engineered congenic mice and persist even after extensive backcrossing.An impressive number of genetically
modified mice have been created since
the techniques for gene targeting in mice
were established in the 1980s by the
2007 Nobel Laureates Mario Capecchi,
Oliver Smithies, and Martin Evans. To
date, at least 11,000 genes have beenspecifically deleted or inactivated in
inbred mice (Hall et al., 2009). Moreover,
institutions like the International Mouse
Phenotype Consortium (IMPC), the Texas
A&M Institute for Genomic Medicine
(TIGM), and the EUCOMMTOOL Project
are engaged in generating collectionsof genetically engineered mutants that
include genetic ablations for all of the
roughly 25,000 protein-coding genes in
the mouse. The comparison of congenic
mice, one bearing a targeted mutation
and one retaining the wild-type (WT) allele
of the gene of interest, is a critical toolnity 43, July 21, 2015 ª2015 Elsevier Inc. 9
ESCs
Figure 1. Myth versus Reality: Passenger
Genome Mutations in Gene-Targeted Mice
(Top) Several mouse chromosome pairs in 129
ESCs are depicted in shades of orange, with a
genetically modified gene of interest indicated
by the red cross. An allele of a non-targeted
gene that is specific to strain 129 is indicated as
a black bar on the chromosome in close proximity
to the targeted DNA. This allele produces a non-
functional protein.
(Middle) The gene-targeted 129 ESCs are utilized
to generate chimeric mice, and these chimeras
are crossed to B6 mice to produce F1 descen-
dants. These progeny bear homologous pairs of
blue B6 and orange 129 chromosomes. However,
the sequence of the allele of the non-targeted
gene in the B6 strain (white bar) differs from
that in the 129 strain and produces a functional
protein.
(Bottom) After repetitive backcrossing of F1 mice
to B6 mice with concomitant selection for de-
scendants carrying the genetically modified
gene, intercrosses of two heterozygotes eventu-
ally generate offspring that are homozygous for
the gene-targeted mutation. The myth of this
approach is that essentially all of the 129-specific
genetic material has been eliminated and the
B6 non-targeted allele is present in these homo-
zygotes. In reality, backcrossing cannot fully
eliminate the 129 passenger genome (orange
regions of blue chromosomes), leading to poten-
tial genomic contamination with the 129-specific
allele of the non-targeted gene (black bar on
blue chromosome). Adapted from Lusis et al.
(2007).
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Previewsfor revealing the biological function of that
gene in vivo. Indeed, such mutants
frequently serve as models for human
genetic diseases, and analyses of these
animals have often led to seminal scienti-
fic discoveries.
Gene-targeted mice are traditionally
generated by modifying the gene of
interest in embryonic stem cells (ESCs)
in vitro using homologous recombination,
an evolutionarily conserved DNA repair
mechanism. The typical procedure in-10 Immunity 43, July 21, 2015 ª2015 Elsevievolves drug-mediated selection of donor
129 ESC clones carrying the introduced
genetic modification, followed by injec-
tion of these ESCs into C57BL/6 (B6)
recipient blastocysts. Some of these
embryos then develop into chimeric
organisms composed of genetically
distinct cells. Identification of chimeras
that underwent germline transmission is
the key to establishing a line of progeny
bearing the desired mutation. ESCs of
various 129 substrains have been origi-
nally chosen for production of genetically
modified mice because they exhibit more
efficient germline transmission and
greater genomic stability in vitro than
B6 ESCs (Gertsenstein et al., 2010).
However, the differences in genomic
background between 129 and B6 ESCs
have the potential to drastically distort
research outcomes. Thus, germline-
transmitting chimeras are routinely back-
crossed to B6 mice for ten or more
generations with concomitant selection
for the introduced mutation. This strategy
is supposed to guarantee that the
donor 129 genome is eliminated from
the descendants. However, the ‘‘passen-
ger genome,’’ which encompasses the
genomic region closely flanking the
targeted locus, remains of donor origin
because recombination frequency dimin-
ishes considerably near the inserted mu-
tation (Figure 1). Previous studies have
shown that genes within the donor 129
passenger genome can differ in nucleo-
tide sequence from the corresponding
allele in the recipient B6 genome (as re-
viewed by Lusis et al., 2007). From
the researcher’s viewpoint, nucleotide
alterations that change the amino acid
sequence of a given protein, so-called
‘‘nonsynonymous substitutions,’’ are
undesirable. Such differences can have
a detrimental impact if the mutated
passenger allele affects the function of
the targeted gene or the experimental
readout. This consequence of the use
of ESCs and recipient mice of differing
genetic backgrounds has long been
known to scientists in the field but is
often discounted. In this issue of
Immunity, Vanden Berghe et al. (2015)
provide an in-depth exploration of
the insidious nature of passenger muta-
tions and the dangers of ignoring their
existence.
In their first analysis, Vanden Berghe
et al. (2015) performed bioinformaticsr Inc.and comparative genomic studies of
various inbred mouse strains using
commonly available online datasets
provided by the Mouse Genome Infor-
matics (MGI, http://www.informatics.jax.
org/), the Mouse Genome Project of the
Wellcome Trust Sanger Institute and the
IMPC (Keane et al., 2011; Yalcin et al.,
2011). Their results show that at least
80% of all gene-targeted mouse strains
generated to date are based on donor
129 ESCs. Comparison of the complete
129 genome with the reference B6
sequence revealed that 1,084 genes
exhibit insertions or deletions of DNA
nucleotides (indels) or single nucleotide
polymorphisms (SNPs) resulting in
nonsynonymous substitutions. Of these
alterations, 13% are nonsense and
63% are frameshift mutations. An
additional 24% of 129 genomic mutations
alter splice donor and acceptor sites,
which could lead to the expression
of splice variants with activities or
functions quite different from those of the
protein encodedby the referenceB6allele.
Strikingly, therefore, almost all genetically
engineered congenic mouse strains
created thus far carry strain129passenger
mutations that could potentially compro-
mise phenotype determination. To illus-
trate the magnitude of the problem, if the
size of the genomic region flanking the tar-
geted gene is fixed to only 1 centimorgan
(1cM), there is still a probability of 0.91
that this region remains of 129 origin
even after 10 backcrosses to B6 mice.
Remarkably, 69% of all genetically modi-
fiedcongenicmicecarry 1 to20passenger
mutations within the 1 cM genomic
region flanking an introduced genetic
modification.
Vanden Berghe et al. (2015) then trans-
lated their in silico findings to live mice
using the well-established model of
lethal lipopolysaccharide (LPS) challenge.
Macrophages infected with a sufficient
number of LPS-bearing Escherichia coli
synthesize lethally high amounts of
interleukin-1b, and caspase-11 (Casp11)
is essential for this production. B6 mice
that bear a functional Casp11 gene there-
fore rapidly succumb to injection of large
amounts of LPS. In contrast, 129 mice ex-
press a Casp11 allele with a 5 base pair
(bp) deletion in the exon 7 splice acceptor
site that leads to an aberrant splicing
product, a frameshift, and a premature
stop codon. This inactivating mutation
Immunity
Previewsof Casp11 protects 129 mice from LPS-
induced death, providing a textbook
illustration of the potential impact of
passenger mutations (Kayagaki et al.,
2011). In their study, Vanden Berghe
et al. (2015) identified a total of 294 genes
within a 10 cM genomic region flanking
the Casp11 gene. They then identified
86 mouse models in which one of these
294 genes had been targeted using 129
ESCs. However, to date, only two of
these models, Casp1-deficient mice and
Birc2-deficient mice, have been demon-
strated to carry the 129-specific inactivat-
ing mutation of Casp11 (Kayagaki et al.,
2011; Kenneth et al., 2012). Vanden
Berghe et al. (2015) therefore investigated
the matrix metalloproteinase Mmp13
gene that resides within a 1 cM DNA
region flanking the Casp11 gene. Despite
more than 10 backcrosses to the B6
strain, the examined Mpp13-ablated
mice still carried the 129-specific Casp11
mutation. Thus, these Mpp13 null mice
were completely protected against a
lethal LPS dose. However, in a different
laboratory, this same Mpp13 null mouse
line was more extensively backcrossed,
lost the inactivating Casp11 passenger
mutation, and was no longer protected
against lethal LPS injection. This example
graphically illustrates how inconsistent
phenotypesmight arise in different labora-
tories purportedly using the same con-
genic mouse line.
In addition to congenic mouse strains,
passenger mutations can affect analyses
of closely related inbred strains. For
example, the IMPC utilizes C57BL/6NJ-
derived ESCs to generate novel strains
of genetically ablated C57BL/6 mice,
and the resulting closely related animals
have been presumed to be untainted by
genomic background effects. However,
Vanden Berghe et al. (2015) identified
about 40 nonsynonymous substitutionswhen they compared the genomes of
C57BL/6NJ and C57BL/6 mice. Tellingly,
C57BL/6NJ mice are much better pro-
tected against lethal LPS injection than
are C57BL/6mice, such that the presence
of passenger mutations literally may ac-
count for the difference between life and
death.
From their bioinformatics analysis,
Vanden Berghe et al. (2015) developed
a Me-PaMuFind web-based tool that
allows researchers to instantly and con-
veniently identify 129-specific passenger
mutations in novel and published gene-
targetedmouse strains. Users can employ
either the gene symbol or the gene data-
base accession number in order to start
their on-line search. The number of back-
crosses can be specified, and the quality
and quantity of potential passenger muta-
tions are listed at the push of a button. In
addition, the program provides the user
with PubMed links to the genes in ques-
tion, as well as direct access to the inven-
tory of genetically modified mouse lines
established by the MGI.
The vast majority of existing and well-
characterized genetically engineered con-
genic mouse strains have been created
utilizing 129 ESCs followed by extensive
backcrosses to the B6 strain. Practicality
dictates that these animals will most likely
persist in future research endeavors.
Thus, awareness of the potential effects
of 129-specific passenger mutations and
disclosure of their presence in a given
experimental mouse model have become
scientific necessities. Fortunately, alter-
native strategies circumventing the use
of 129 ESCs to generate genetically modi-
fied mutants are now available. Culture
conditions for B6 ESCs have been greatly
improved over the past couple of years
(Gertsenstein et al., 2010; Lin et al.,
2014), making it easier to preserve the
B6 genetic background. Moreover, Van-Immunden Berghe et al.’s cautionary tale turns
a glaring spotlight on the choice of ESC
type to be modified using the game-
changing CRISPR/Cas genome engi-
neering technology (Ledford, 2015). The
wake-up call represented by this Immunity
article on the importance of the passenger
genome therefore does a great public ser-
vice to the research community involved
in the analysis and generation of gene-
targeted mice.
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